Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology

被引：0

作者：

Comini-Frota, Elizabeth Regina ^{[1
,4
]}

Vasconcelos, Claudia C. F. ^{[2
,4
]}

Mendes, Maria Fernando ^{[3
,4
]}

机构：

[1] Univ Jose do Rosario Vellano, UNIFENAS, Belo Horizonte, MG, Brazil

[2] Univ Fed Estado Rio de Janeiro, Dept Neurol, Rio De Janeiro, RJ, Brazil

[3] Santa Casa Sao Paulo, Dept Neurol, Sao Paulo, SP, Brazil

[4] Acad Brasileira Neurol, Dept Cient Neuroimunol DCNI, Sao Paulo, SP, Brazil

来源：

ARQUIVOS DE NEURO-PSIQUIATRIA | 2017年 / 75卷 / 01期

关键词：

multiple sclerosis; Consensus; treatment; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; TREATMENT STRATEGIES; EMERGING THERAPIES; CONTROLLED PHASE-3; CLINICAL-TRIALS; MULTICENTER; 1ST-LINE; EFFICACY;

D O I：

10.1590/0004-282X20160185

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Multiple sclerosis has become an ever-increasing challenge to neurologists. With the release of the latest medications on the market, Brazilian neurologists feel divided between following their patients' evolution in accordance with the strict rules established by the Brazilian Ministry of Health regarding drug distribution, or following disease progression and worsening in accordance with the evidence in the literature. Therefore, a systematic review of the main published treatment guidelines was conducted and an escalating therapy proposed for guiding multiple sclerosis patient treatment in Brazil.

引用

页码：57 / 65

页数：9

共 32 条

[1]

[Anonymous], 2013, n+1, V17, DOI DOI 10.1093/NDT/GFV100

[2] GRADE guidelines: 3. Rating the quality of evidence [J].

Balshem, Howard ;

Helfand, Mark ;

Schuenemann, Holger J. ;

Oxman, Andrew D. ;

Kunz, Regina ;

Brozek, Jan ;

Vist, Gunn E. ;

Falck-Ytter, Yngve ;

Meerpohl, Joerg ;

Norris, Susan ;

Guyatt, Gordon H. .

JOURNAL OF CLINICAL EPIDEMIOLOGY, 2011, 64 (04) :401-406

[3] Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy [J].

Broadley, Simon A. ;

Barnett, Michael H. ;

Boggild, Mike ;

Brew, Bruce J. ;

Butzkueven, Helmut ;

Heard, Robert ;

Hodgkinson, Suzanne ;

Kermode, Allan G. ;

Lechner-Scott, Jeannette ;

Macdonell, Richard A. L. ;

Marriott, Mark ;

Mason, Deborah F. ;

Parratt, John ;

Reddel, Stephen W. ;

Shaw, Cameron P. ;

Slee, Mark ;

Spies, Judith ;

Taylor, Bruce V. ;

Carroll, William M. ;

Kilpatrick, Trevor J. ;

King, John ;

McCombe, Pamela A. ;

Pollard, John D. ;

Willoughby, Ernest .

JOURNAL OF CLINICAL NEUROSCIENCE, 2014, 21 (11) :1847-1856

[4] Current and emerging therapies in multiple sclerosis: a systematic review [J].

Castro-Borrero, Wanda ;

Graves, Donna ;

Frohman, Teresa C. ;

Flores, Angela Bates ;

Hardeman, Paula ;

Logan, Diana ;

Orchard, Megan ;

Greenberg, Benjamin ;

Frohman, Elliot M. .

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2012, 5 (04) :205-220

[5] Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis [J].

Clerico, M. ;

Faggiano, F. ;

Palace, J. ;

Rice, G. ;

Tintore, M. ;

Durelli, L. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (02)

[6] Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial [J].

Cohen, Jeffrey A. ;

Coles, Alasdair J. ;

Arnold, Douglas L. ;

Confavreux, Christian ;

Fox, Edward J. ;

Hartung, Hans-Peter ;

Havrdova, Eva ;

Selmaj, Krzysztof W. ;

Weiner, Howard L. ;

Fisher, Elizabeth ;

Brinar, Vesna V. ;

Giovannoni, Gavin ;

Stojanovic, Miroslav ;

Ertik, Bella I. ;

Lake, Stephen L. ;

Margolin, David H. ;

Panzara, Michael A. ;

Compston, D. Alastair S. .

LANCET, 2012, 380 (9856) :1819-1828

[7]

Confavreux C, 2014, HAND CLINIC, V122, P343, DOI 10.1016/B978-0-444-52001-2.00014-5

[8] Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action [J].

Damal, Kavitha ;

Stoker, Emily ;

Foley, John F. .

BIOLOGICS-TARGETS & THERAPY, 2013, 7 :247-258

[9] The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis [J].

Doerr, Jan ;

Paul, Friedemann .

CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2015, 17 (06)

[10] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

← 1 2 3 4 →